The function of CD28 molecules that are present on malignant plasma cells of human myeloma cell lines (HMCL) was studied. First, myeloma cells expressed a similar density of CD28 antigen to that of normal T cells. The myeloma CD28 molecules were able to bind B7-Ig molecules as well as L cells transfected with a B7-1 cDNA, and anti-CD28 mAb inhibited the binding. Myeloma cells did not express B7-1 antigens but a low density of B7-2 antigens. The myeloma B7-2 molecules of two HMCL were able to bind CTLA-4 protein. No autocrine CD28:B7-2 activation could be evidenced as we found no spontaneous binding of the p85 subunit of PI-3 kinase to CD28 molecules. In addition, a blocking anti-CD28 mAb did not affect the IL-6-dependent or autonomous proliferation of the HMCL. The activation of myeloma CD28 molecules with or without TPA stimulation did not affect the proliferation, survival, differentiation, expression of activation antigens and cytokine receptors or cytokine production of myeloma cells. However, the triggering of myeloma CD28 molecules by B7-1 transfectant cells resulted in binding of the p85 subunit of PI-3 kinase to CD28 molecules as previously shown for T cell CD28 molecules. This expression of a large density of CD28 molecules able to bind B7 molecules might contribute to a downregulation of the immune control of myeloma cells.
Introduction
In the process of T cell activation by antigen-presenting cell (APC), activation of CD28 molecules present on T cells has been shown to be essential. As recently reviewed, 1,2 T cell activation by APC requires at least three steps: (1) binding of APC to T cells through adhesion molecules such as ICAM-1:LFA-1 and LFA-3:CD2; (2) presentation of peptide antigen bound to molecules of the major histocompatibility complex of APC to the T cell receptor; and (3) activation of the T cell CD28 molecules or related receptors by their counter receptors B7-1 (CD80) or B7-2 (CD86) present on APC. A disruption of the CD28:B7-1 interaction may result in induction of T cell anergy. 1 CD28 activation has been shown to be critical in inducing IL-2 secretion in activated T cells. 1, 2 More recently, activation of CD28 molecules was shown to induce activation of phosphatidyl-inositol 3-kinase (PI-3) in T cells [3] [4] [5] [6] [7] and to promote survival by upregulating bcl-X L expression. 8 In an early report, CD28 molecules were found to be present on human malignant plasma cells. 9 A high expression of CD28 molecules on a large panel of human myeloma cell lines (HMCL) 10 or on freshly explanted myeloma cells was recently confirmed. 11 The present study demonstrates for the first time that the CD28 molecule expressed on malignant plasma cells is functional. It is able to bind its counter receptors, the B7 molecules, and this binding induces activation of PI-3 kinase in myeloma cells. 
Materials and methods

Antibodies and reagents
The agonist (CD28.2) and antagonist (CD28.6) anti-CD28 mAbs were obtained as described elsewhere. 12 MAbs against CD3, CD16, CD25, CD56, CD69, B7-1, HLA-DR antigens, FITC-conjugated (FabЈ) 2 fragments of goat antibodies to mouse IgG and FITC-conjugated antibodies to Fc fragments of human Ig, IgG1 and IgG2 murine control antibodies (recognizing no human antigens) were purchased from Immunotech (Marseille, France), mAbs to CD40, CD40L, B7-2 antigens from Pharmingen (San Diego, CA, USA), magnetic beads coated with anti-CD19, anti-CD14 or anti-murine Ig antibodies from Dynal (Oslo, Norway).
The human B7-1-human Ig and human CTLA-4-human Ig fusion proteins (B7-1-Ig and CTLA-4-Ig) were kindly provided by Dr Linsley (Bristol Myers Squibb, Seattle, WA, USA). Purified IL-6 was provided by Dr Ytier (Ares Serono, Geneva, Switzerland) and neutralizing AH-65 anti-IL-6 mAb by Dr Brailly (Immunotech). The B-T2 anti-gp130 mAbs were obtained by our group. 13, 14 PHA and purified human Ig were purchased from Sigma (St Louis, MO, USA). Rabbit antibodies to p85 subunit of PI-3 kinase or phosphotyrosine were purchased from UBI (Lake Placid, NY, USA) or Transduction Laboratories (Lexington, KY, USA). Peroxidase-conjugated antibodies to mouse or rabbit antibodies and the ECL detection kit were purchased from Amersham (Buckinghamshire, UK). Tritiated thymidine was purchased from CEA (Saclay, France).
Cell lines
The XG-1 and XG-6 IL-6-dependent HMCL were obtained in our laboratory 10 and the RPMI8226 and U266 HMCL were purchased from ATCC (Rockville, MD, USA). The XG cells were cultured in culture medium (RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine and 5 × 10 −5 M 2-mercaptoethanol) and with 1 ng/ml of IL-6. The RPMI8226 and U266 cells were routinely cultured in culture medium without IL-6. Murine L cell fibroblasts transfected with human B7-1 cDNA (B7-1 L cell) and parental L cells were generously provided by Dr A Truneh (Smith Kline Beecham, Philadelphia, PA, USA). Human CD28 transfectant (DWT6.11) was obtained by transfecting full-length human CD28 cDNA in pH␤-pr-neo vector into murine T cell hybridoma. 6 These cell lines were cultured in culture medium. All cell lines were free of mycoplasma contamination as assayed using an ELISA kit from Boehringer (Mannheim, Germany).
Analysis of survival of myeloma cells
To investigate the effects of CD-28 molecule on the survival of the human myeloma cells, XG-6 cells were washed once with culture medium, incubated for 5 h at 37°C in culture medium alone, and washed again twice to remove recombinant bound IL-6. Cells (3 × 10 5 cells/ml) were then cultured with either culture medium alone or with the activating CD28.2 anti-CD28 mAb (10 g/ml) or with 1 ng/ml of IL-6. A mouse IgG1 anti-CD3 mAb was used as a control antibody. After 24, 48 and 72 h of culturing, the percentage of viable cells was determined by the trypan blue dye exclusion method, and apoptotic cells were detected by propidium iodide staining and flow cytometry. Apoptotic cells had a DNA content inferior to that of cells in the G1 phase of the cell cycle. 
Flow cytometry
CD28 adhesion assays
Myeloma cells were labeled with 51 Chrome and washed twice. Cells were incubated for 1 h at 20°C in culture medium containing 10 mM EDTA either with isotype-matched control mAb or with the mAbs to be tested for the inhibition of adhesion. Labeled cells (5 × 10 4 cells per well in 200 l of culture medium) were then added to monolayers of B7-1 L cells or control parental L cells. Adhesion was initiated by centrifugation and continued at 37°C for 1 h. Monolayers were washed five times with ice-cold RPMI 1640 medium, solubilized by addition of 0.5 M NaOH and the radioactivity was counted in a gamma counter. The percentage of myeloma cells that bound to B7-1 L cell monolayer was estimated by subtracting the radioactivity in control L cell monolayer (due to the non-specific adhesion of myeloma cells to L cells) from the radioactivity in B7-1 L cell monolayer and dividing the result by the total radioactivity of the labeled cells added to culture wells.
Allogenic mixed lymphocyte reaction (allo-MLR)
Heparinized-venous peripheral blood from one healthy volunteer was collected under EDTA after written informed consent. T lymphocytes were purified by depletion of non-T cells with mAbs and magnetic beads. Monocytes and B cells were depleted using CD14 and CD19-coated microbeads. Then, non-T cells were removed by incubation with a cocktail of mAbs to CD16, CD56 and HLA-DR antigens and goat antimouse Ig microbeads. After two rounds of purification, the purity of CD3 cells was always higher than 98%. Cells were frozen in 50% FCS/10% DMSO at 20 × 10 6 cells per vial. To evaluate myeloma cell-induced T cell proliferation, primary allogenic MLR was performed using irradiated (3000 rads) XG-6 HMCL cocultured at 5 × 10 4 cells/well with 10 5 allogenic T cells in 96-well round-bottomed plates in RPMI1640 and 5% heat-inactivated human AB serum. When indicated, agonist (CD28.2) or antagonist (CD28.6) anti-CD28 mAbs or their isotypic controls were added at 10 g/ml. Purified T cells were also cultured with PHA (1 g/ml). After 5 days of coculture, cells were pulsed with 1 Ci of tritiated thymidine for 12 h, harvested and counted. All microculture tests were carried out in triplicate.
Proliferation and immunoglobulin production of myeloma cells
To investigate the effect of activation of CD28 molecules on the proliferation of myeloma cells, cells were washed once with culture medium, incubated for 5 h at 37°C in culture medium alone to remove bound IL-6, and washed again twice. Myeloma cells were then cultured with various concentrations of the CD28.2 activating anti-CD28 mAb or control mAb with or without TPA (100 ng/ml; Sigma) in 96-well flatbottomed microplates for 2 or 5 days. We used a mouse IgG1 anti-CD3 mAb that did not bind to myeloma cells as a control antibody. In some experiments, the effect of the blockage of CD28 activation by the CD28.6 neutralizing anti-CD28 mAb was investigated by adding 10 g/ml of the anti-CD28 mAb in 5-day cultures of XG cells with IL-6 (100 pg/ml) or of RPMI8226 and U266 cells. At the end of the culture, 0.5 Ci of tritiated thymidine (25 Ci/mM; CEA, Saclay) were added to each culture well for 8 h and tritiated thymidine incorporation was determined on six replicate culture wells. To evaluate the production of immunoglobulin, myeloma cells (10 5 cells/ml) were cultured with various concentrations of the activating CD28.2 anti-CD28 mAb or the anti-CD3 control mAb for 2 days and the concentration of human kappa or lambda immunoglobulin light chains was determined by ELISA as previously reported. 15 
Immunoprecipitation and immunoblotting
Myeloma cells or CD28 transfected cells (10 × 10 6 cells in 1 ml) were incubated with B7-1 L cells (5 × 10 6 ) at 37°C in RPMI 1640 complete medium for 5 min. B7-1 L cells had been previously incubated with anti-B7-1 mAb or an isotypematched control mAb (10 g per ml). Cells were lysed for 1 h at 4°C end over end with lysis buffer (50 mM Hepes, 150 mM NaCl, 10% glycerol, 1% Triton, 1.5 mM MgCl 2 , 1 mM EGTA, 10 g/ml leupeptin, 1 mM PMSF, 1 mM Na orthovanadate, 100 mM pyrophosphate, 100 mM NaF, 10 mM DTT). After preclearing at 14 000 g, the lysates were immunoprecipitated for 2 h at 4°C using the CD28.2 mAb or isotype-matched control mAb and protein G-sepharose beads (Pharmacia, Uppsala, Sweden). Immunoprecipitated samples were resolved in 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany). Membranes were blocked for 1 h at room temperature in 138 mM NaCl, 3 mM KCl, 25 mM Tris-HCl (pH 7.4), 0.1% Tween 20 (TBS-T), 5% bovine serum albumin (BSA), then incubated for 1 h at room temperature with a polyclonal rabbit antiserum to p85 subunit of PI-3 kinase (UBI, Lake Placid, NY, USA). The primary antibodies were visualized with peroxidase-conjugated donkey anti-rabbit immunoglobulins (at 1:10 000 dilution in TBS-T)
Figure 1
Comparison of membrane expression of CD28 molecule on myeloma cells and human peripheral T lymphocytes. Cells from the U266, RPMI8226, XG-1 and XG-6 myeloma cell lines and peripheral blood mononuclear cells from two healthy donors were stained with the CD28.6 anti-CD28 mAb (solid line) or an isotype-matched control murine mAb (dotted line) and FITC-conjugated F(abЈ) 2 fragments of goat anti-mouse immunoglobulin. The fluorescence was analyzed by flow cytometry using a FACScan.
and by an enhanced chemiluminescence (ECL) detection system. The membranes were stripped with 100 mM glycin, pH 2.2, 0.1% NP 40 and 1% SDS for 30 min twice, reprobed with the CD28.6 anti-CD28 mAb and peroxidase-conjugated sheep anti-mouse immunoglobulins (at 1:10 000 dilution in TBS-T) and bands were visualized with an ECL kit. Additional membranes were prepared, probed with rabbit anti-phosphotyrosine antibodies and peroxidase-conjugated donkey antirabbit antibodies and bands were visualized with an ECL detection system.
Results
Expression of CD28 antigen on human myeloma cell lines
Results are outlined in Figure 1 . All the cells of the four HMCL expressed the CD28 molecules as indicated by the labeling with anti-CD28 mAb. Peripheral blood T cells from two healthy donors were labeled with the same anti-CD28 mAb and analyzed on the same day and with the same FACS para- Binding of B7-1 antigen by CD28 molecules on myeloma cells
As illustrated in Figure 2 , a significant shift of the fluorescence profile was observed when myeloma cells were incubated with B7-1-Ig molecules and FITC-labeled anti-human Ig antibodies as compared to cells incubated with FITC-labeled antihuman Ig antibodies alone. The more marked shift was observed for U266 cells (Figure 2 ) in agreement with their higher expression of CD28 molecules (Figure 1) . By using peripheral blood T cells from healthy individuals, only a slight shift of the fluorescence profile was observed (Figure 2 ). The ability of myeloma cell CD28 molecules to bind B7-1 protein was further demonstrated by the binding of radiolabeled myeloma cells to B7-1 L cells. As indicated in Figure 3 , 26.4 and 24% of XG-6 and U266 myeloma cells, respectively, were able to bind to B7-1 L cells. An anti-B7-1 mAb blocked this binding by 90 and 70% respectively. An anti-CD28 mAb also 
XG-6 Ͻ5% 10% Ͻ5% (20) Myeloma cells were incubated with anti-B7-1 or anti-B7-2 mAbs or CTLA4-Ig or control antibodies. Cells were then labeled with a FITC conjugated goat anti-murine Ig or anti-human Ig antibody. Fluorescence was analyzed with a flow cytometer and results are the percentage of cells labeled by the different antibodies. In brackets is indicated the mean density of the fluorescence profiles. The fluorescence intensities obtained with a control murine mAb (recognizing no human antigens) or human Ig were set between 4 and 6.
blocked it indicating that myeloma cells failed to express CTLA-4, the other counter-receptor for B7-1 and B7-2 molecules.
Expression of the family of B7 molecules on myeloma cells
Myeloma cells did not express B7-1. They expressed weakly the B7-2 antigen. For two cell lines, RPMI8226 and XG-1, a detectable binding of CTLA-4-Ig molecules to B7-2 molecules was found (Table 1) .
Lack of obvious biological effects of CD28 activation in myeloma cells
In order to investigate a biological effect of CD28 activation in myeloma cells, we looked for a modulation of myeloma cell proliferation. We also looked for a change in the expression of various antigens as well as in cytokine or immunoglobulin production. Myeloma cells were activated by the CD28.2 anti-CD28 mAb known to activate T cell CD28 molecules. 12 This was further confirmed in the experiments shown in Figure 4 . Indeed, allogenic T cells were poorly stimulated by irradiated XG-6 myeloma cells. Addition of CD28.2 anti-CD28 mAb, unlike CD28.6 mAb, dramatically increased T cell proliferation induced by irradiated myeloma cells.
Upon removal of IL-6, XG-6 cells died by apoptosis within 3 days ( Figure 5 ). Addition of agonist CD28.2 mAb did not delay the apoptosis of XG-6 cells ( Figure 5 ). We found no increase or decrease of the myeloma cell proliferation when myeloma cells were cultured with the agonist CD28.2 or the antagonist CD28.6 mAbs with or without TPA ( Figure 6 ). In particular, activation of CD28 molecules was unable to support the proliferation of the IL-6-dependent XG-1 and XG-6 HMCL. This is in agreement with the lack of induction of IL-6 production in this HMCL by the CD28.2 mAb and TPA (results not shown). Activation of CD28 molecules did not induce expression of CD25, CD40L, CD69, B7-1 or HLA-DR antigens (Table 2) . It did not affect the expression of CD38, CD40, B7-2, IL-6R or gp130 IL-6 transducer, or modify the low Ig production by myeloma cells ( Table 2) .
Binding of PI-3 kinase to myeloma CD28 molecules CD28 immunoprecipitates were easily detectable in U266 cells contrary to XG-6 cells ( Figure 7 ) in agreement with the higher CD28 expression in U266 cells (Figure 1 ). The binding of U266 or XG-6 myeloma cells to B7-1 L cells induced the coimmunoprecipitation of the p85 subunit of the PI-3 kinase with CD28 molecules. Pre-incubation of myeloma cells with anti-B7-1 mAb inhibited binding of P85 to myeloma CD28 (Figure 7) . No detectable binding of P85 to CD28 could be detected in myeloma cells without exogenous activation of CD28 (Figure 7) . For the two myeloma cell lines, we failed to detect phosphorylation of the myeloma CD28 molecules (results not shown). This was not surprising since phosphorylation of CD28 T cell molecules was rarely found 3 except for CD28 transfectants that expressed a very large density of CD28 molecules. 6 
Discussion
The current study shows that myeloma cells from HMCL express a similar density of CD28 molecules to that of freshly explanted T cells. We have shown that the myeloma cell CD28 molecules are functional molecules in term of binding to the B7 counter receptor using either B7-Ig molecules or L cells transfected with B7-1 human cDNA. The CD28.6 anti-CD28 mAb inhibited the binding to B7-1 L cells indicating that myeloma cells do not express CTLA-4 molecules, a second receptor for B7-1 molecules. CTLA-4 molecules were recently shown to be expressed on B cells activated by T cells. 16 Malignant human plasma cells are, at present, the only cells that are found to express a functional CD28 molecule together with T cells. 1, 2 As normal plasma cells fail to express CD28 17 and as activation of CD28 antigen is a crucial event for induction of functional T cells (mainly by triggering IL-2 production) and prevention from apoptosis, 8 one might suspect a major role of CD28 activation for myeloma cell proliferation, survival or differentiation. Our previous studies have shown that IL-6 was a growth factor for myeloma cells 18 and that IL-6-dependent myeloma cell lines could be reproducibly obtained from patients with terminal disease. 10 By using the agonist CD28.2 mAb (known to activate T cells) in combination with TPA, 12 we found no modulation of the proliferation of the IL-6-dependent XG-1 and XG-6 HMCL or of the autonomously growing RPMI8226 and U266 HMCL. This is in agreement with a lack of modulation by the anti-CD28 mAbs of IL-6R and gp130 IL-6 transducer expression on myeloma cells or of IL-6 production by myeloma cells. We also found that triggering of myeloma CD28 by agonist CD28.2 anti-CD28 mAb or B7-1 L cells did not abrogate or delay the apoptotic death of myeloma cells that occurred upon removal of IL-6. This negative result was noteworthy because CD28 activation has been shown to prevent T cells from apoptosis by increasing the bcl-X L anti-apoptotic protein. 8 Finally, we found no induction or modulation of the expression of several activation antigen or cytokines known to be induced on CD28-activated T cells (CD25, CD69, CD40L) as well as no change in the Ig production. A lack of obvious function of activation of CD28 antigen on myeloma cells might be explained by an already optimal autocrine activation of the CD28 molecules by the B7-2 molecules present in low density on myeloma cells. Our present results may rule out this hypothesis since we found no modulation of myeloma cell proliferation or Ig production by adding a blocking anti-CD28 mAb.
In order to further elucidate whether activation of myeloma CD28 could have some biological effects, we looked for activation of signal transduction. We failed to detect tyrosine phosphorylation of myeloma CD28 upon binding of myeloma cells to B7-1 L cells. This is not surprising since phosphorylation of T cell CD28 is generally not detected.
3 Such phosphorylation was reported for CD28 transfectants that expressed a very large CD28 density. 6 If attempts to demonstrate T cell CD28 phosphorylation have generated equivocal results, several groups have shown that CD28 activation resulted in the binding of the P85 subunit of PI-3 kinase and activation of this kinase. [2] [3] [4] [5] [6] We found similar findings for
Figure 5
Activation of CD28 did not prevent myeloma cells from apoptosis. XG-6 myeloma cells were extensively washed to remove IL-6 and cultured for 72 h at a concentration of 3 × 10 5 cells/ml in culture medium supplemented with 10% of FCS and either 1 ng/ml of IL-6 (left panel), no cytokine (middle panel) or 10 g/ml of the agonist CD28.2 anti-CD28 mAb (right panel). At the end of the culture, DNA content was assayed by propidium iodide staining. Cells in apoptosis had a DNA content inferior to that of the G1 phase of the cell cycle.
Table 2
Activation of myeloma CD28 molecules did not change antigen expression and immunoglobulin production by myeloma cells (14) 82 ( Agonist or antagonist anti-CD28 mAb did not stimulate or inhibit myeloma cell proliferation. Myeloma cells (10 4 cells/100 l/culture well) were cultured for 5 days with 10 g/ml of an anti-CD3 control mAb (control mAb), 50 pg/ml or 100 pg/ml of IL-6 and 10 g/ml of an anti-CD3 control mAb (IL6 (50 pg) and IL6 (100 pg)), 50 pg/ml of IL-6 and 10 g/ml of the antagonist CD28.6 anti-CD28 mAb (IL6 (50 pg) + antagonist CD28.6 Ab),10 g/ml of the agonist CD28.2 anti-CD28 mAb with (TPA + agonist CD28.2 Ab) or without (agonist CD28.2 Ab) 100 ng/ml of TPA, or 10 g/ml of the antagonist CD28.6 anti-CD28 mAb with (TPA + antagonist CD28.6 Ab) or without (antagonist CD28.6 Ab) 100 ng/ml of TPA, or with 100 ng/ml of TPA (TPA). Cell proliferation was evaluated by tritiated thymidine incorporation. Results are mean values ± s.d. of tritiated thymidine incorporation determined on sextuplate culture wells.
Figure 7
Binding of p85 of PI-3 kinase to myeloma CD28 molecule. U266 or XG-6 myeloma cells were stimulated by B7-1-transfected L cells with or without 10 g/ml of a B7-1mAb. The CD28-transfected murine T cell hybridoma DWT6.11 was used as positive control. After stimulation, cells were lysed and immunoprecipitation was performed with the CD28.2 mAb. After SDS-PAGE and transfer to membrane, the membranes were incubated with anti-p85 rabbit antibodies (upper panel) or CD28 mAb (CD28.6, lower panel). After extensive washes, the bound antibodies were revealed by anti-rabbit (upper panel) or anti-mouse immunoglobulins (lower panel) coupled to peroxidase and enhanced chemoluminescence. U266: lanes 1, 2 and 3; XG-6: lanes 4, 5 and 6; DWT6.11: lanes 7 and 8. Unstimulated cells, lanes 1 and 4; cells stimulated by B7-1 L cells, lanes 2 and 5; cells stimulated by B7-1 L cells and anti-B7-1 mAb, lanes 3 and 6; DWT6.11 stimulated by B7-1 L cells, lane 7. Lane 8 corresponds to DWT6.11 total cell lysate. myeloma CD28, especially for U266 cells that expressed a large density of CD28. No spontaneous PI-3 kinase binding to CD28 was found and this also rules out a detectable autocrine activation of CD28 molecules by the endogenous B7-2 molecules present on myeloma cells.
The lack of effects of CD28 activation on the proliferation/differentiation of myeloma cells may be due to the fact that myeloma cell lines are obtained only from patients with extramedullary proliferation. 10 In patients with chronic disease, although IL-6 is still a tumor growth factor, 19, 20 additional signals provided by the tumoral environment are necessary for the long-term proliferation of myeloma cells in vivo. As B7-1 molecules are present on stromal cells, activation of CD28 molecules might be one of these signals. Finally, the ability of myeloma CD28 to bind B7 molecules could block the antigen presenting capacity of myeloma cells and contribute to the escape of the tumoral clone from immune surveillance.
